Valuation Metrics Reflect Improved Price Attractiveness
Apollo Hospitals currently trades at a price of ₹7,639.20, slightly down by 0.84% from the previous close of ₹7,704.10. Despite this minor dip, the stock’s valuation metrics have improved significantly, signalling enhanced price attractiveness. The price-to-earnings (P/E) ratio stands at 60.56, which, while elevated, is considered attractive within the context of its sector and historical averages. This is a marked improvement from prior assessments where the valuation was deemed fair.
The price-to-book value (P/BV) ratio is at 12.10, reflecting the premium investors are willing to pay for the company’s equity relative to its book value. Although high, this is consistent with the hospital sector’s growth prospects and Apollo’s market leadership. The enterprise value to EBITDA (EV/EBITDA) ratio of 32.55 further supports the attractive valuation narrative, especially when compared to peers such as Max Healthcare, which trades at a very expensive EV/EBITDA of 46.36.
Comparative Peer Analysis
When juxtaposed with Max Healthcare, Apollo Hospitals’ valuation metrics appear more reasonable. Max Healthcare’s P/E ratio is 66.34, and its PEG ratio stands at 1.80, both higher than Apollo’s respective 60.56 and 1.57. This relative valuation advantage underscores Apollo’s improved standing in the eyes of investors and analysts alike.
Moreover, Apollo’s return on capital employed (ROCE) at 17.91% and return on equity (ROE) at 18.39% highlight the company’s efficient utilisation of capital and shareholder funds, reinforcing the justification for its current valuation levels.
Strong Market Capitalisation and Mojo Score Upgrade
Apollo Hospitals is classified as a large-cap stock, which typically offers greater stability and liquidity. The company’s Mojo Score has been upgraded to 78.0, with the Mojo Grade moving from Hold to Buy as of 13 April 2026. This upgrade reflects improved fundamentals, valuation, and momentum, signalling increased confidence from the MarketsMOJO analytical framework.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Stock Performance Outpaces Sensex Over Long Term
Apollo Hospitals has delivered impressive returns over multiple time horizons, significantly outperforming the Sensex benchmark. Year-to-date, the stock has gained 8.47%, while the Sensex has declined by 9.75%. Over one year, Apollo’s return is 9.85% compared to the Sensex’s negative 4.15%. The three-year and five-year returns are even more striking, with Apollo delivering 69.01% and 138.80% respectively, dwarfing the Sensex’s 25.86% and 57.67% gains.
Over a decade, Apollo Hospitals has generated a staggering 482.15% return, more than doubling the Sensex’s 200.37% growth. This long-term outperformance underscores the company’s resilience and growth trajectory within the hospital sector.
Financial Health and Dividend Yield
Despite its premium valuation, Apollo Hospitals maintains a modest dividend yield of 0.26%, reflecting a focus on reinvestment and growth rather than high dividend payouts. The company’s EV to capital employed ratio of 8.24 and EV to sales ratio of 4.74 further indicate efficient capital utilisation and revenue generation relative to enterprise value.
These metrics, combined with a PEG ratio of 1.57, suggest that the stock’s price growth is reasonably aligned with its earnings growth prospects, supporting the attractive valuation grade.
Thinking about Apollo Hospitals Enterprise Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Sector Outlook and Investment Considerations
The hospital sector continues to benefit from rising healthcare demand, increasing insurance penetration, and technological advancements. Apollo Hospitals, as a sector leader, is well positioned to capitalise on these trends. Its valuation improvement to an attractive grade suggests that the market is recognising these growth drivers more favourably.
However, investors should remain mindful of the relatively high valuation multiples, which imply expectations of sustained earnings growth. Any slowdown in sector growth or operational challenges could pressure the stock’s premium pricing.
Nonetheless, Apollo’s strong returns on capital, consistent market outperformance, and upgraded Mojo Grade to Buy provide a compelling case for inclusion in a diversified portfolio focused on quality large-cap healthcare stocks.
Conclusion
Apollo Hospitals Enterprise Ltd.’s recent valuation grade upgrade from fair to attractive reflects a meaningful shift in price attractiveness, supported by solid financial metrics and superior market performance. The company’s P/E ratio of 60.56 and EV/EBITDA of 32.55 compare favourably against peers, while its robust ROCE and ROE underpin operational efficiency.
With a large-cap status and a Mojo Score of 78.0, Apollo Hospitals stands out as a strong buy candidate for investors seeking exposure to the hospital sector’s growth story. While valuation multiples remain elevated, the company’s fundamentals and long-term returns justify the premium, making it a noteworthy addition to healthcare-focused portfolios.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
